Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Oct 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a treatment called prothrombin complex concentrate (PCC) works for patients experiencing severe bleeding after a traumatic injury. There is some uncertainty about when it's best to use PCC and how effective it is, so this study aims to gather more information on its safety and effectiveness in managing major bleeding in trauma patients.

To participate in this trial, you need to be between 18 and 80 years old and have experienced a trauma that required treatment in a hospital's emergency department. You should also be admitted to the hospital within 24 hours after your injury and have a certain level of blood loss. However, if you have used PCC before coming to the hospital, are on certain blood-thinning medications, or have specific medical conditions, you may not be eligible. If you join the study, you’ll receive care according to the trial guidelines, and your progress will be monitored by medical professionals. The trial is currently recruiting participants, and your involvement could help improve future treatments for severe bleeding after trauma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years old or \< 80 years old
• • 2. Trauma treated in resuscitation unit/emergency room patient
• • 3. Hospital admission within 24h after injury
• • 4. Assessment of blood consumption (ABC) score ≥2 points.
• Exclusion Criteria:
• • 1. PCC was used before admission
• • 2. Anticoagulant drugs (such as low molecular weight heparin, rivaroxaban, warfarin, etc.)
• • 3. Previous venous thrombosis (VTE, Patients with a history of coronary artery stents within 3 months of pulmonary embolism and myocardial infarction)
• • 4. Patients with traumatic cardiac arrest in hospital
• • 5. Women during breastfeeding, pregnancy or pregnancy
• • 6. Patients with hemophilia A and other blood system diseases, severe liver disease, cirrhosis and other coagulation dysfunction